Literature DB >> 14687013

Non-lateralized pain in a case of chronic paroxysmal hemicrania?

L J M M Mulder1, E L H Spierings.   

Abstract

We describe a man with chronic paroxysmal hemicrania, who remained free of headaches on indomethacin, 25 mg once or twice daily. However, in this case, in contrast to typical cases of paroxysmal hemicrania, the pain of the headaches was nonlateralized and was located in the centre of the forehead. The headaches were not associated with local autonomic symptoms or signs involving the eyes or nose. Initially, the pain of the headaches lasted for seconds only and was brought on by coughing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14687013     DOI: 10.1111/j.1468-2982.2004.00635.x

Source DB:  PubMed          Journal:  Cephalalgia        ISSN: 0333-1024            Impact factor:   6.292


  5 in total

Review 1.  Paroxysmal hemicrania: an update.

Authors:  Sanjay Prakash; Rushad Patell
Journal:  Curr Pain Headache Rep       Date:  2014-04

2.  Can paroxysmal hemicrania be bilateral? A case report.

Authors:  Yildiz Degirmenci; Hulusi Kececi
Journal:  Neurol Sci       Date:  2016-03-29       Impact factor: 3.307

Review 3.  Indomethacin-responsive headaches.

Authors:  Juliana VanderPluym
Journal:  Curr Neurol Neurosci Rep       Date:  2015       Impact factor: 5.081

4.  The myth of the normal, average human brain--the ICBM experience: (1) subject screening and eligibility.

Authors:  John C Mazziotta; Roger Woods; Marco Iacoboni; Nancy Sicotte; Kami Yaden; Mary Tran; Courtney Bean; Jonas Kaplan; Arthur W Toga
Journal:  Neuroimage       Date:  2008-08-15       Impact factor: 6.556

Review 5.  Therapeutical approaches to paroxysmal hemicrania, hemicrania continua and short lasting unilateral neuralgiform headache attacks: a critical appraisal.

Authors:  Carlo Baraldi; Lanfranco Pellesi; Simona Guerzoni; Maria Michela Cainazzo; Luigi Alberto Pini
Journal:  J Headache Pain       Date:  2017-07-20       Impact factor: 7.277

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.